USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AVIRON
Address:
297 N BERNARDO AVE
MOUNTAIN VIEW, CA 94043
Phone:
(650) 919-6553
URL:
N/A
EIN:
770309686
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $806,137.00 9
SBIR Phase II $2,434,867.00 4

Award List:

Improved Influenza a and B Virus Vaccines

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Shengqiang Li
Abstract:
Improved replication of vaccine seed strains in embryonated hens' eggs would lower the cost of manuinactivated influenza vaccines and allow more doses to be manufactured. Higher-growing influenza A aviruses will be developed that can be genetically reasserted with poorly-growing fresh human… More

DEVELOPMENT OF RATIONALLY DESIGNED HCMV VACCINE STRAINS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$99,537.00
Agency:
HHS
Principal Investigator:
Kemble, george w
Abstract:
N/a

RATIONAL DESIGN OF A LIVE, ATTENUATED HSV2 VACCINE

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$99,737.00
Agency:
HHS
Principal Investigator:
Kemble, George W
Abstract:
N/a

Clinical Trials of a Genetically Engineered HCMV

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$753,388.00
Agency:
HHS
Principal Investigator:
Kemble, george w
Abstract:
N/a

MUCOSAL IMMUNITY & REPLICATION OF HUMAN CYTOMEGALOVIRUS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$332,942.00
Agency:
HHS
Principal Investigator:
George W. Kemble
Abstract:
Not Available Faster and more efficient methods are needed for developing scenario-based team and individual performance measures for distributed simulation environments. Aptima proposes a steamlined approach to identify critical team competencies, knowledge, and skills. This approach combines… More

BOVINE PARAINFLUENZA 3 VIRUS AS A NOVEL VACCINE VECTOR

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$99,784.00
Agency:
HHS
Principal Investigator:
Aurelia A. Haller
Abstract:
Not Available Q-Peak, Inc. proposes to develop a broadly tunable, l0-W-average-power IR source suitable for use as a DIAL system transmitter and based on the combination of a Nd-doped pulsed pump laser and optical parametric oscillators (OPO) The laser source, a compact, diode-pumped, 5-10 kHz… More

CHIMERIC RSV SUBGROUP A AND B VACCINE CANDIDATES

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$99,137.00
Agency:
HHS
Principal Investigator:
Hong Jin
Abstract:
Not Available Physical Sciences Inc., Thiokol Propulsion, and Lockheed Martin Missile and Space propose to develop spacecraft structural materials which can withstand mechanical loads during launch and can be consumed as propellants for on-orbit propulsion. Spacecraft structural elements… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Hong Jin
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$653,200.00
Agency:
HHS
Principal Investigator:
Hong Jin
Abstract:
N/a

Generation of bPIV3-vectored PIV and RSV Vaccines

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Aurelia A. Haller
Abstract:
N/a

Generation of bPIV3-vectored PIV and RSV Vaccines

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$602,329.00
Agency:
HHS
Principal Investigator:
Aurelia A. Haller
Abstract:
N/a

DEVELOPMENT OF A LIVE ATTENUATED HSV-2 VACCINE

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Mark N. Prichard
Abstract:
DESCRIPTION: (Adapted from Applicant's Abstract) Genital herpes is a major health problem in the U.S. The prevalence of these infections is dramatically increasing despite effective antiviral drugs. This increase puts young adults and infants at risk of genital and neonatal… More

DEVELOPMENT OF A LIVE ATTENUATED HSV-2 VACCINE

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$425,950.00
Agency:
HHS
Principal Investigator:
Mark N. Prichard
Abstract:
DESCRIPTION: (Adapted from Applicant's Abstract) Genital herpes is a major health problem in the U.S. The prevalence of these infections is dramatically increasing despite effective antiviral drugs. This increase puts young adults and infants at risk of genital and neonatal… More